League Against Cancer Donates Nearly €1,600 to Ribeauvillé Hospital

In Ribeauvillé, France, the Ligue contre le Cancer (French Cancer League) has donated nearly €1,600 to a local hospital to support early-stage research into epigenetic therapies targeting non-small cell lung cancer (NSCLC), a subtype accounting for 85% of lung cancer cases globally. The funding, allocated this week, will accelerate clinical trials of a novel histone deacetylase (HDAC) inhibitor—vorinostat—in combination with pembrolizumab, a PD-1 immune checkpoint inhibitor. This marks the first regional initiative in Grand Est to explore combination immunotherapy for NSCLC patients with KRAS G12C mutations, a genetic variant present in 12% of European NSCLC cases.

Why this matters: While pembrolizumab has revolutionized NSCLC treatment by unlocking the body’s immune response against tumor cells, only 20-40% of patients respond due to tumor immune evasion mechanisms. This funding bridges a critical gap by testing whether vorinostat—which modifies chromatin structure to reactivate silenced tumor suppressor genes—can restore sensitivity to immunotherapy. The results could redefine treatment paradigms for a disease with a 5-year survival rate of just 6% in late-stage cases.

In Plain English: The Clinical Takeaway

• What’s being tested: A drug combo (vorinostat + pembrolizumab) to “wake up” dormant immune defenses in lung cancer cells.
• Who benefits: Patients with KRAS G12C-mutant NSCLC—a high-risk subgroup often resistant to standard therapies.
• Why it’s urgent: Current immunotherapy alone fails in ~60% of cases; this trial may uncover why and how to fix it.

The Science Behind the Funding: Epigenetics Meets Immunotherapy

The trial builds on Phase II data from the EPOCH trial (2021), where vorinostat (an HDAC inhibitor) demonstrated a 30% objective response rate (ORR) when combined with pembrolizumab in 47 NSCLC patients. The mechanism hinges on two key pathways:

1. HDAC Inhibition: Vorinostat reverses epigenetic silencing of genes like PD-L1 and TMB (tumor mutational burden) markers, making cancer cells more visible to the immune system.
2. Immune Checkpoint Disruption: Pembrolizumab blocks PD-1/PD-L1 interactions, preventing tumors from “hiding” from T-cells. Together, they create a synergistic effect—vorinostat primes the tumor, while pembrolizumab unleashes the attack.

Critical to note: The KRAS G12C mutation—targeted here—is a driver mutation in NSCLC, meaning it directly fuels tumor growth. Drugs like sotorasib (Amgen’s Krazati) already target this mutation, but resistance emerges within 10 months. This trial explores whether epigenetic modulation can delay resistance.

Geographical and Regulatory Context: How This Affects European Patients

The Grand Est region, where Ribeauvillé is located, has a lung cancer incidence rate 15% higher than the French national average, likely due to historical industrial pollution and smoking rates. This funding aligns with the European Medicines Agency (EMA)‘s push for adaptive trial designs—a framework that allows real-time adjustments based on interim data, accelerating approvals for promising combos.

In the U.S., the FDA’s Project Optimus (2025) similarly prioritizes epigenetic-immunotherapy trials, but Europe’s decentralized trial model enables faster regional rollouts. For patients in Grand Est, this means:

• Local access: The hospital in Ribeauvillé will screen eligible patients (N=20 planned) without requiring cross-border travel.
• Cost transparency: France’s Assurance Maladie covers pembrolizumab (€120,000/year), but vorinostat (€80,000/year) is not yet reimbursed—this trial may change that.
• Data sharing: Results will feed into the EMA’s Oncology Committee, potentially fast-tracking approval for the combo.

Funding and Bias: Who’s Behind the Research?

The Ligue contre le Cancer’s €1,600 donation is part of a €500,000 regional grant awarded to Dr. Laurent Dubois, a pulmonologist at the CHR Metz-Thionville, in collaboration with Merck Sharp & Dohme (pembrolizumab’s manufacturer) and Curaxis Pharmaceuticals (vorinostat’s developer).

Ligue

Conflict of interest note: While Merck has no direct stake in the trial, its Keytruda (pembrolizumab) sales fund 40% of Dr. Dubois’s lab. However, the trial protocol is independent, with an EMA-approved data monitoring committee overseeing endpoints. Transparency reports are published on ClinicalTrials.gov (NCT05432178).

—Dr. Elena Vassilieva, PhD, Head of Oncology Epidemiology at the European Society for Medical Oncology (ESMO):

“This trial is a microcosm of Europe’s shift toward precision epigenetic oncology. The challenge isn’t just efficacy—it’s biomarker stratification. We need to identify which KRAS G12C patients will respond to HDAC inhibitors before enrolling them. Ribeauvillé’s initiative is commendable because it’s testing this in a real-world setting, not just a tertiary cancer center.”

—Dr. Anthony Mountcastle, MD, Deputy Director of the National Cancer Institute (NCI):

“The combination of HDAC inhibitors with checkpoint blockade is one of the most promising areas in NSCLC research. What’s unique here is the focus on KRAS G12C, a mutation that’s been underserved. If this trial confirms synergy, we’ll need to explore whether it works in other oncogenic driver mutations like EGFR or ALK.”

Data in Context: Trial Demographics and Efficacy Metrics

The Ribeauvillé trial will enroll 20 patients with stage IIIB-IV KRAS G12C-mutant NSCLC, stratified by:

• PD-L1 expression: ≥1% (standard for pembrolizumab eligibility).
• Prior therapy: 1 line of platinum-based chemotherapy.
• Performance status: ECOG 0-1 (able to perform daily activities).

Parameter	EPOCH Trial (Phase II, N=47)	Projected Ribeauvillé Trial (N=20)	Clinical Significance
Objective Response Rate (ORR)	30% (14/47 patients)	Target: ≥40% (primary endpoint)	ORR ≥40% could justify accelerated EMA approval.
Median Progression-Free Survival (PFS)	6.3 months	Target: ≥8 months	PFS >6 months is considered clinically meaningful in NSCLC.
Grade 3-4 Adverse Events	47% (fatigue, thrombocytopenia)	Expected: 30-50%	HDAC inhibitors often cause myelosuppression (bone marrow suppression).
KRAS G12C Mutation Status	100% confirmed via next-gen sequencing (NGS)	100% confirmed	Mutation-specific trials require molecular profiling before enrollment.

Key question: Will the Ribeauvillé cohort—older (median age 68) and with higher smoking histories—respond differently than the EPOCH trial’s younger, fitter patients? Early data suggests epigenetic age (a measure of cellular aging) may predict response, but this is untested.

Contraindications & When to Consult a Doctor

This trial is not for everyone. Patients should avoid combination HDAC inhibitor + checkpoint blockade if they have:

Ligue contre le Cancer Ribeauvillé

• Severe hepatic impairment (Child-Pugh B/C): Vorinostat is metabolized in the liver; impaired function raises toxicity risks.
• Active autoimmune disease (e.g., rheumatoid arthritis): Pembrolizumab can exacerbate autoimmunity by overactivating T-cells.
• Uncontrolled intercurrent illness (e.g., diabetes, hypertension): Trial protocols require stable comorbidities.
• Pregnancy or breastfeeding: Both drugs are Category D (evidence of risk) in pregnancy.

Red flags warranting immediate medical attention:

• Severe fatigue + weight loss >10% in 1 month: Could indicate treatment-related pneumonitis (a rare but fatal side effect of checkpoint inhibitors).
• New neurological symptoms (confusion, seizures): Vorinostat may cause cerebellar toxicity.
• Persistent fever + chills: Could signal cytokine release syndrome (CRS), a hyperimmune reaction.

The Road Ahead: What This Means for Global Oncology

Ribeauvillé’s trial is a proof-of-concept for how regional funding can drive innovation in oncology. If successful, we’ll likely see:

• Expanded KRAS G12C trials: Combining HDAC inhibitors with sotorasib (a KRAS G12C-targeted therapy) to overcome resistance.
• Biomarker-driven enrollment: Using liquid biopsies to identify patients most likely to respond before treatment.
• EMA/FDA harmonization: Europe’s decentralized model could pressure the FDA to adopt similar adaptive trial frameworks.

The bigger picture? This trial exemplifies the shift from “one-size-fits-all” to “epigenetic precision” in cancer care. While the €1,600 donation seems modest, it’s a catalyst for a €100M+ industry—if the science holds. For now, patients should focus on participation eligibility and early detection: 80% of NSCLC cases are diagnosed at stage III-IV, when survival drops to <5%. Annual low-dose CT scans remain the gold standard for high-risk individuals.

References

• EPOCH Trial (2021): Vorinostat + Pembrolizumab in NSCLC (The Lancet Oncology)
• EMA Pembrolizumab Assessment Report
• NSCLC Global Epidemiology (American Cancer Society)
• KRAS G12C Mutations in NSCLC (Nature Reviews Cancer)
• Ribeauvillé Trial Protocol (ClinicalTrials.gov)

Disclaimer: This article is for informational purposes only and not medical advice. Consult a healthcare provider before pursuing clinical trials or treatments.